Why Is Congress Targeting These Six Medicines In Drug Price Hearing?
US Congressional Hearing Will Look At Mature Brands
Executive Summary
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
You may also be interested in...
US Industry Welcomes Nomination Of Califf To FDA Helm For A Second Time
The US off-patent industry has welcomed the news that Robert Califf looks likely to serve a second term as US Food and Drug Administration commissioner, after his nomination by US President Joe Biden.
Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing
Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.
Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing
Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.